- Cetuximab, a monoclonal antibody used primarily in the treatment of colorectal cancer and head and neck squamous cell carcinoma, is becoming an increasingly integral part of modern oncology protocols due to its targeted mechanism of action against the epidermal growth factor receptor (EGFR), contributing to improved patient outcomes and more personalized cancer therapies
- The rising demand for cetuximab is primarily fueled by the growing global cancer burden, increasing awareness and screening initiatives for early cancer detection, and a shift toward biologics and targeted therapies in oncology treatment paradigms
- North America dominates the cetuximab market with the largest revenue share of 49.5% in 2024, characterized by advanced healthcare infrastructure, favorable reimbursement frameworks, and a high incidence of colorectal and head & neck cancers. The U.S., in particular, shows robust usage trends due to early adoption of biologics and continued research into combination therapies involving cetuximab
- Asia-Pacific is expected to be the fastest growing region in the cetuximab market during the forecast period due to improving healthcare access, increasing healthcare expenditure, and rising cancer prevalence, particularly in populous countries such as China and India
- Head and neck cancer segment dominates the cetuximab market with a market share of 50.5% in 2024, driven by its proven efficacy in treating squamous cell carcinoma and its widespread use in combination with radiotherapy or chemotherapy
